JP2012520323A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520323A5
JP2012520323A5 JP2011554236A JP2011554236A JP2012520323A5 JP 2012520323 A5 JP2012520323 A5 JP 2012520323A5 JP 2011554236 A JP2011554236 A JP 2011554236A JP 2011554236 A JP2011554236 A JP 2011554236A JP 2012520323 A5 JP2012520323 A5 JP 2012520323A5
Authority
JP
Japan
Prior art keywords
medicament according
dimer
taxane
medicament
colchicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011554236A
Other languages
English (en)
Japanese (ja)
Other versions
JP5725563B2 (ja
JP2012520323A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027159 external-priority patent/WO2010105172A1/en
Publication of JP2012520323A publication Critical patent/JP2012520323A/ja
Publication of JP2012520323A5 publication Critical patent/JP2012520323A5/ja
Application granted granted Critical
Publication of JP5725563B2 publication Critical patent/JP5725563B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011554236A 2009-03-13 2010-03-12 チオコルヒチン誘導体との組み合わせ療法 Active JP5725563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21007409P 2009-03-13 2009-03-13
US61/210,074 2009-03-13
PCT/US2010/027159 WO2010105172A1 (en) 2009-03-13 2010-03-12 Combination therapy with thiocolchicine derivatives

Publications (3)

Publication Number Publication Date
JP2012520323A JP2012520323A (ja) 2012-09-06
JP2012520323A5 true JP2012520323A5 (https=) 2013-04-18
JP5725563B2 JP5725563B2 (ja) 2015-05-27

Family

ID=42728818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554236A Active JP5725563B2 (ja) 2009-03-13 2010-03-12 チオコルヒチン誘導体との組み合わせ療法

Country Status (12)

Country Link
US (2) US20120189701A1 (https=)
EP (1) EP2405750B1 (https=)
JP (1) JP5725563B2 (https=)
KR (1) KR101739598B1 (https=)
CN (1) CN102427728A (https=)
AU (2) AU2010224012B2 (https=)
BR (1) BRPI1008955A2 (https=)
CA (1) CA2755121A1 (https=)
IL (1) IL215079A (https=)
MX (1) MX2011009452A (https=)
NZ (1) NZ595189A (https=)
WO (1) WO2010105172A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2131821B1 (en) * 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス, エルエルシー 再発性癌の処置のための方法および組成物
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
US20160143866A1 (en) * 2014-11-21 2016-05-26 Eli D. Ehrenpreis Combination Therapy for Administration of Monoclonal Antibodies
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-vegf 항체
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
MXPA00011821A (es) 1998-05-29 2004-07-30 Scripps Research Inst Metodos y composiciones utiles para la modulacion de la angiogenesis usando tirosina-cinasa src.
EP1171117A4 (en) 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
US20040143004A1 (en) 2002-02-26 2004-07-22 Joseph Fargnoli Metronomic dosing of taxanes
DK1539157T3 (da) 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
EP1750706B1 (en) 2004-06-01 2016-10-05 University Of Virginia Patent Foundation Dual small molecule inhibitors of cancer and angiogenesis
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
CN101077335A (zh) * 2007-06-29 2007-11-28 济南康泉医药科技有限公司 一种含酪氨酸激酶抑制剂的抗癌组合物

Similar Documents

Publication Publication Date Title
JP2012520323A5 (https=)
Batool et al. A detailed insight of the tumor targeting using nanocarrier drug delivery system
Liang et al. Monotherapy and combination therapy using anti‐angiogenic nanoagents to fight cancer
Boateng et al. Delivery of nanoparticle-based radiosensitizers for radiotherapy applications
Edis et al. Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives
Duan et al. Advances and prospects in the treatment of pancreatic cancer
Pugazhendhi et al. Inorganic nanoparticles: a potential cancer therapy for human welfare
Shrestha et al. Nanoparticles‐mediated combination therapies for cancer treatment
Lee et al. A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment
Tang et al. The use of nanoparticulates to treat breast cancer
Yao et al. Mesoporous silica nanoparticles capped with graphene quantum dots for potential chemo–photothermal synergistic cancer therapy
JP2013527232A5 (https=)
Zhang et al. Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer
Liu et al. Gold nanorods/mesoporous silica-based nanocomposite as theranostic agents for targeting near-infrared imaging and photothermal therapy induced with laser
Mahmoudi et al. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy
Yong et al. Tungsten sulfide quantum dots as multifunctional nanotheranostics for in vivo dual-modal image-guided photothermal/radiotherapy synergistic therapy
Alsaab et al. Nanomaterials for antiangiogenic therapies for cancer: a promising tool for personalized medicine
RU2009121568A (ru) Комбинации и способы введения терапевтических агентов и комбинированная терапия
Bao et al. Synergistic effect of tangeretin and atorvastatin for colon cancer combination therapy: targeted delivery of these dual drugs using RGD peptide decorated nanocarriers
JP2013533232A5 (https=)
Yadav et al. Novel nanomaterials as photo‐activated cancer diagnostics and therapy
JP2010509331A5 (https=)
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
Gu et al. Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma
Mushtaq et al. The wonders of X-PDT: an advance route to cancer theranostics